三部推拿法对慢性失眠患者NEI网络调节的影响及LC-MS代谢组学研究

注册号:

Registration number:

ITMCTR2200006726

最近更新日期:

Date of Last Refreshed on:

2022-10-31

注册时间:

Date of Registration:

2022-10-31

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

三部推拿法对慢性失眠患者NEI网络调节的影响及LC-MS代谢组学研究

Public title:

Effects of three-part manipulation on NEI network regulation in patients with chronic insomnia and LC-MS metabolomics study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

三部推拿法对慢性失眠患者NEI网络调节的影响及LC-MS代谢组学研究

Scientific title:

Effect of Three-part Manipulation on NEI Network Regulation in Patients with Chronic Insomnia and LC-MS Metabolomics Study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200065189 ; ChiMCTR2200006726

申请注册联系人:

马亮亮

研究负责人:

周运峰

Applicant:

Ma Liangliang

Study leader:

Zhou Yunfeng

申请注册联系人电话:

Applicant telephone:

15136263527

研究负责人电话:

Study leader's telephone:

13803846101

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

838297018@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zyf5680198@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

河南省郑州市金水区东明路63号

研究负责人通讯地址:

河南省郑州市金水区东明路63号

Applicant address:

63 Dongming Road, Jinshui District, Zhengzhou City, Henan Province

Study leader's address:

63 Dongming Road, Jinshui District, Zhengzhou City, Henan Province

申请注册联系人邮政编码:

Applicant postcode:

450003

研究负责人邮政编码:

Study leader's postcode:

450003

申请人所在单位:

河南中医药大学第三附属医院

Applicant's institution:

The Third Affiliated Hospital of Henan University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2022HL-019

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

河南中医药大学第三附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Third Affiliated Hospital of Henan University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/9/20 0:00:00

伦理委员会联系人:

高翔

Contact Name of the ethic committee:

Gao Xiang

伦理委员会联系地址:

河南省郑州市金水区东明路63号

Contact Address of the ethic committee:

63 Dongming Road, Jinshui District, Zhengzhou City, Henan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 371 56283180

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河南中医药大学第三附属医院

Primary sponsor:

The Third Affiliated Hospital of Henan University of Chinese Medicine

研究实施负责(组长)单位地址:

河南省郑州市金水区东明路63号

Primary sponsor's address:

63 Dongming Road, Jinshui District, Zhengzhou City, Henan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南

市(区县):

郑州

Country:

China

Province:

Henan

City:

Zhengzhou

单位(医院):

河南中医药大学第三附属医院

具体地址:

金水区东明路63号

Institution
hospital:

The Third Affiliated Hospital of Henan University of Chinese Medicine

Address:

63 Dongming Road, Jinshui District

经费或物资来源:

中原院士基金项目(NO. ZYQR201912120)

Source(s) of funding:

Zhongyuan Academician Foundation of China (NO. ZYQR201912120)

研究疾病:

慢性失眠

研究疾病代码:

Target disease:

Chronic insomnia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

1.整体评价三部推拿法对慢性失眠患者睡眠质量、日间功能状态影响的行为学指标变化。 2.探讨三部推拿法对慢性失眠患者NEI网络相关睡眠因子的影响,与睡眠质量和日间功能状态的相关性,为推拿治疗慢性失眠提供生物学标志物和作用靶点。 3.基于LC-MS代谢组学技术分析慢性失眠患者血清的代谢组学特征,寻找共有代谢物和差异代谢物,探讨潜的代谢生物标志物及代谢通路,以期为三部推拿法干预提供病理生理基础。 4.阐释三部推拿法治疗慢性失眠的内在机制,为临床慢性失眠的治疗提供更多依据和选择。

Objectives of Study:

1. To comprehensively evaluate the behavioral index changes of the influence of the three-part massage method on sleep quality and daytime functional status of patients with chronic insomnia. 2. To explore the effect of three-part massage on sleep factors related to NEI network in patients with chronic insomnia, and its correlation with sleep quality and daytime functional status, so as to provide biological markers and targets for massage treatment of chronic insomnia. 3. To analyze the metabolomic characteristics of serum of patients with chronic insomnia based on LC-MS metabolomics technology, to find common and differential metabolites, and to explore potential metabolic biomarkers and metabolic pathways, so as to provide the pathophysiological basis for the three-part massage intervention. 4. Explain the internal mechanism of the treatment of chronic insomnia with three massage methods, and provide more basis and choice for the treatment of clinical chronic insomnia.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合CI诊断标准及心脾两虚型诊断标准; 2.45周岁≤年龄≤65周岁者,性别不限; 3.匹兹堡睡眠指数(PSQI)指数≥7分; 4.汉密尔顿抑郁量表17项版本(HAMD-17)评分≤17分; 5.汉密尔顿焦虑量表(HAMA)评分≤14分; 6.签署知情同意书,自愿参加本项研究者。

Inclusion criteria

1. Meet the diagnostic criteria of CI and the diagnostic criteria of heart and spleen deficiency; 2.45 years old ≤65 years old, both genders; 3. Pittsburgh Sleep Index (PSQI) ≥7; 4. Hamilton Depression Scale 17-item version (HAMD-17) score ≤17; 5. Hamilton Anxiety Scale (HAMA) score ≤14; 6. Signed the informed consent and volunteered to participate in the study.

排除标准:

1.患有其它类型的睡眠障碍如呼吸相关性睡眠障碍、不宁腿综合征、环境性睡眠困难、睡眠不足综合征、短睡眠者等。 2.存在有其它精神障碍、人格障碍以及物质或药物滥用/依赖者; 3.合并有脑器质性疾病及其他躯体疾病者,进展性恶性肿瘤或其它严重消耗性疾病,易合并感染和出血者; 4.近2周曾服用抗抑郁药物、抗精神病药物以及镇静催眠类药物者; 5.推拿治疗部位皮肤有感染者或为超敏皮肤; 6.妊娠及哺乳期妇女; 7.其他原因研究者认为不适宜参加临床试验者。

Exclusion criteria:

1. Patients with other types of sleep disorders such as respiratory related sleep disorder, restless legs syndrome, environmental sleep difficulties, sleep deprivation syndrome, short sleepers, etc. 2. The presence of other mental disorders, personality disorders and substance or substance abuse/dependence; 3. Patients with organic brain diseases and other physical diseases, progressive malignant tumors or other serious wasting diseases, and easy to be complicated with infection and bleeding; 4. Patients who have taken antidepressants, antipsychotics and sedative and hypnotic drugs in the past 2 weeks; 5. Massage treatment site of the skin infected or hypersensitive skin; 6. Pregnant and lactating women; 7. For other reasons, the investigator considers it inappropriate to participate in the clinical trial.

研究实施时间:

Study execute time:

From 2022-09-20

To      2024-12-31

征募观察对象时间:

Recruiting time:

From 2022-11-01

To      2023-12-31

干预措施:

Interventions:

组别:

对照组

样本量:

32

Group:

control group

Sample size:

干预措施:

常规推拿法

干预措施代码:

Intervention:

traditional regular tui na

Intervention code:

组别:

试验组

样本量:

32

Group:

treatment group

Sample size:

干预措施:

三部推拿法

干预措施代码:

Intervention:

three-part manipulation group

Intervention code:

样本总量 Total sample size : 64

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

河南

市(区县):

郑州

Country:

China

Province:

Henan

City:

Zhengzhou

单位(医院):

河南中医药大学第三附属医院

单位级别:

三级甲等中医医院

Institution/hospital:

The Third Affiliated Hospital of Henan University of Chinese Medicine

Level of the institution:

Third class A Chinese medicine hospital

测量指标:

Outcomes:

指标中文名:

白细胞介素1

指标类型:

次要指标

Outcome:

Interleukin, IL-1

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

5-羟色胺

指标类型:

次要指标

Outcome:

5-hydroxytryptamine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子

指标类型:

次要指标

Outcome:

tumor necrosis factor, TNF

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮质醇

指标类型:

次要指标

Outcome:

cortisol, CORT

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谷氨酸

指标类型:

次要指标

Outcome:

glutamate, Glu

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

促肾上腺皮质激素

指标类型:

次要指标

Outcome:

adrenocorticotrophic hormone, ACTH

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

液质联用代谢组学分析

指标类型:

主要指标

Outcome:

liquid chromatography-mass spectrometry,LC-MS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

主要指标

Outcome:

Pittsburgh Sleep Quality Index, PSQI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

γ-氨基丁酸

指标类型:

次要指标

Outcome:

γ-aminobutyric acid, GABA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疲劳量表-14

指标类型:

次要指标

Outcome:

Fatigue Scale-14,FS-14

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

失眠严重程度量表

指标类型:

次要指标

Outcome:

Insomnia Severity Index,ISI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞介素6

指标类型:

次要指标

Outcome:

Interleukin, IL-6

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 45
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用简单随机法,应用软件IBM SPSS statistics 23(版本号:R23.0.0.0 32位软件商:IBM)在计算机上产生随机号码,按照随机数大小排序,较小的32例为试验组,较大的32例为对照组,然后按照随机号码生成的序列放入依顺序编码的密封不透光的信封中。

Randomization Procedure (please state who generates the random number sequence and by what method):

Using the simple random method, the application software IBM SPSS Statistics 23 (version No. : R23.0.0.0 32-bit software vendor: IBM) generated random numbers on the computer and sorted them according to the size of the random numbers. The smaller 32 cases were the experimental group and the larger 32 c

盲法:

本试验采用单盲设计,临床操作者、评价者、统计者三者分离,由临床治疗医师负责随机分组并进行全程治疗,由全程不知分组的经过系统培训的人员进行纳入评定并做治疗后效果评价;由专门统计人员进行数据处理,保证治疗过程、疗效评价及统计分析过程的客观、公正。

Blinding:

This trial adopted a single-blind design, with clinical operators, evaluators and statisticians separated. Clinical therapists were responsible for randomization and the whole treatment, and systematically trained personnel who did not know the whole group were included in the evaluation and the post-treatment effect evaluation. Data processing by specialized statisticians ensures the objectivity and justice of the treatment process, therapeutic effect evaluation and statistical analysis.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

公开方式:试验完成后公开;公开原始数据日期:预计2024年12月底;公众查询:采用临床试验公共管理平台。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Disclosure method: After the trial is completed, the date of disclosure of the original data: expected by end of December 2024; public inquiry: the clinical trial public management platform is used

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

原始的数据记录及病例记录表,纸质版由实验负责人保存;电子版采用EXCEL及SPSS格式进行保存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All of the original data records and case records, the paper version materials is preserved by experimental operator, and the electronic version records is saved by using EXCEL and SPSS software.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统